A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus
Latest Information Update: 10 Mar 2026
At a glance
Most Recent Events
- 05 Mar 2026 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2025 Planned number of patients changed from 80 to 104.
- 29 Jan 2025 New trial record